FindMyKOL
Clinical trialNCT04299113Active, not recruitingPhase 1Interventional

Mocetinostat With Vinorelbine in Children, Adolescents & Young Adults With Refractory and/or Recurrent Rhabdomyosarcoma

NCT04299113 is a phase 1 interventional trial sponsored by Jonsson Comprehensive Cancer Center. As of 21 Nov 2026, it is active and no longer recruiting. It studies Mocetinostat and Vinorelbine in Rhabdomyosarcoma. The registry lists an enrollment of 14 participants at 1 site in 1 country. The registry lists a start date of 14 May 2020 and a primary completion date of 30 Dec 2026.

View the registry record on ClinicalTrials.gov

Key facts

Registry attributes as recorded on the ClinicalTrials.gov study record.

Key facts for NCT04299113
FieldValue
Registry IDNCT04299113
StatusActive not recruiting
PhasePhase 1
Study typeInterventional trial
Lead sponsorJonsson Comprehensive Cancer Center
Enrollment14
Registered sites1
Countries1
ConditionsRhabdomyosarcoma
DrugsMocetinostat and Vinorelbine
Start14 May 2020
Primary completion30 Dec 2026
Study completion30 Dec 2027
Last update posted17 Jul 2026

Registered summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This phase I trial studies the side effects and best dose of mocetinostat when given together with vinorelbine to see how well it works in treating children, adolescents, and young adults with rhabdomyosarcoma that has spread to nearby tissues or lymph nodes and cannot be removed by surgery (locally advanced unresectable) or has spread to other places in the body (metastatic), and does not respond to treatment (refractory) or has come back (relapsed). Mocetinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as vinorelbine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving mocetinostat and vinorelbine may work better in treating children, adolescents, and young adults with rhabdomyosarcoma compared to vinorelbine alone.

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

California, United States1 site
  • Rebecca Phelan

    Los Angeles

United States, by state

AlaskaAKMaineMEVermontVTNew HampshireNHWashingtonWAMontanaMTNorth DakotaNDMinnesotaMNWisconsinWIMichiganMINew YorkNYMassachusettsMARhode IslandRIOregonORIdahoIDSouth DakotaSDIowaIAIllinoisILIndianaINOhioOHPennsylvaniaPANew JerseyNJConnecticutCTCalifornia: 1 siteCA1NevadaNVWyomingWYNebraskaNEMissouriMOKentuckyKYWest VirginiaWVVirginiaVAMarylandMDDelawareDEArizonaAZUtahUTColoradoCOKansasKSArkansasARTennesseeTNNorth CarolinaNCSouth CarolinaSCNew MexicoNMOklahomaOKLouisianaLAMississippiMSAlabamaALGeorgiaGAHawaiiHITexasTXFloridaFLDistrict of ColumbiaDC
Fewer sitesMore sites

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

MocetinostatVinorelbine →
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Questions about NCT04299113

Each answer restates registry values shown on this page.

What is NCT04299113?

NCT04299113 is a phase 1 interventional trial sponsored by Jonsson Comprehensive Cancer Center. It studies Mocetinostat and Vinorelbine in Rhabdomyosarcoma.

Is NCT04299113 recruiting?

As of 21 Nov 2026, it is active and no longer recruiting.

Who leads NCT04299113?

The registry names Noah C. Federman, MD (principal investigator, University of California at Los Angeles) as the overall official.

Where does NCT04299113 run?

The registry lists 1 site in 1 country. Every site with a stated country is in one country: United States.

Which drugs does NCT04299113 study?

The registered drug and biological interventions are Mocetinostat and Vinorelbine.

When is NCT04299113 expected to complete?

The registry lists a primary completion date of 30 Dec 2026 and a study completion date of 30 Dec 2027. The sponsor last updated the record on 17 Jul 2026.

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.